{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T06:45:04Z","timestamp":1771569904412,"version":"3.50.1"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,3,5]],"date-time":"2020-03-05T00:00:00Z","timestamp":1583366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Physiol."],"DOI":"10.3389\/fphys.2020.00184","type":"journal-article","created":{"date-parts":[[2020,3,5]],"date-time":"2020-03-05T05:47:20Z","timestamp":1583387240000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Inhibition of Myostatin Reduces Collagen Deposition in a Mouse Model of Oculopharyngeal Muscular Dystrophy (OPMD) With Established Disease"],"prefix":"10.3389","volume":"11","author":[{"given":"Pradeep","family":"Harish","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leysa","family":"Forrest","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanti","family":"Herath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Dickson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Malerba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Popplewell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,3,5]]},"reference":[{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1186\/s13395-017-0141-y","article-title":"A mouse anti-myostatin antibody increases muscle mass and improves muscle strength and contractility in the mdx mouse model of Duchenne muscular dystrophy and its humanized equivalent, domagrozumab (PF-06252616), increases muscle volume in cynomolgus monkeys.","volume":"7","author":"Andre","year":"2017","journal-title":"Skelet. Muscle"},{"key":"B3","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/j.exger.2013.06.004","article-title":"A myostatin inhibitor (propeptide-Fc) increases muscle mass and muscle fiber size in aged mice but does not increase bone density or bone strength.","volume":"48","author":"Arounleut","year":"2013","journal-title":"Exp. Gerontol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1002\/cpdd.386","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of domagrozumab (PF-06252616), an antimyostatin monoclonal antibody, in healthy subjects.","volume":"7","author":"Bhattacharya","year":"2017","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1212\/wnl.55.9.1267","article-title":"Oculopharyngeal MD among bukhara jews is due to a founder (GCG)9 mutation in the PABP2 gene.","volume":"55","author":"Blumen","year":"2000","journal-title":"Neurology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1096\/fj.04-2796com","article-title":"Myostatin propeptide-mediated amelioration of dystrophic pathophysiology.","volume":"19","author":"Bogdanovich","year":"2005","journal-title":"FASEB J."},{"key":"B7","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/ng0298-164","article-title":"Short GCG expansions in the PABP2 gene cause oculopharyngeal muscular dystrophy.","volume":"18","author":"Brais","year":"1998","journal-title":"Nat. Genet."},{"key":"B8","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1002\/mus.25268","article-title":"Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial.","volume":"55","author":"Campbell","year":"2017","journal-title":"Muscle Nerve"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1073\/pnas.1525795113","article-title":"Anti-myostatin antibody increases muscle mass and strength and improves insulin sensitivity in old mice.","volume":"113","author":"Camporez","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B10","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/nm1242","article-title":"Doxycycline attenuates and delays toxicity of the oculopharyngeal muscular dystrophy mutation in transgenic mice.","volume":"11","author":"Davies","year":"2005","journal-title":"Nat. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1097\/NEN.0b013e3181aa31c2","article-title":"Endomysial fibrosis in duchenne muscular dystrophy: a marker of poor outcome associated with macrophage alternative activation.","volume":"68","author":"Desguerre","year":"2009","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1080\/21678707.2018.1536542","article-title":"Advances in emerging therapeutics for oculopharyngeal muscular dystrophy.","volume":"6","author":"Harish","year":"2018","journal-title":"Exp. Opin. Orphan Drugs"},{"key":"B13","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1089\/hum.2015.014","article-title":"Progress on gene therapy, cell therapy, and pharmacological strategies toward the treatment of oculopharyngeal muscular dystrophy.","volume":"26","author":"Harish","year":"2015","journal-title":"Hum. Gene Ther."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1002\/jcsm.12438","article-title":"Inhibition of myostatin improves muscle atrophy in oculopharyngeal muscular dystrophy (OPMD).","volume":"10","author":"Harish","year":"2019","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15153","article-title":"Activin a more prominently regulates muscle mass in primates than does GDF8.","volume":"8","author":"Latres","year":"2017","journal-title":"Nat. Commun."},{"key":"B16","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1093\/gerona\/glp068","article-title":"Myostatin inhibition enhances the effects of exercise on performance and metabolic outcomes in aged mice.","volume":"64","author":"LeBrasseur","year":"2009","journal-title":"J. Gerontol. Ser. A"},{"key":"B17","doi-asserted-by":"publisher","first-page":"19371","DOI":"10.1074\/jbc.M802585200","article-title":"Myostatin directly regulates skeletal muscle fibrosis.","volume":"283","author":"Li","year":"2008","journal-title":"J. Biol. Chem."},{"key":"B18","doi-asserted-by":"publisher","first-page":"3957","DOI":"10.1242\/jcs.090365","article-title":"Inhibition of myostatin reverses muscle fibrosis through apoptosis.","volume":"125","author":"Li","year":"2012","journal-title":"J. Cell Sci."},{"key":"B19","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0022-510X(82)90001-6","article-title":"Oculopharyngeal muscular dystrophy: an autopsied case from the french-canadian kindred.","volume":"53","author":"Little","year":"1982","journal-title":"J. Neurol. Sci."},{"key":"B20","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.omtn.2016.11.009","article-title":"Systemic antisense therapeutics for dystrophin and myostatin exon splice modulation improve muscle pathology of adult mdx mice.","volume":"6","author":"Lu-Nguyen","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1038\/mt.2015.88","article-title":"Combination antisense treatment for destructive exon skipping of myostatin and open reading frame rescue of dystrophin in neonatal mdx mice.","volume":"23","author":"Lu-Nguyen","year":"2015","journal-title":"Mol. Ther."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14848","article-title":"PABPN1 gene therapy for oculopharyngeal muscular dystrophy.","volume":"8","author":"Malerba","year":"2017","journal-title":"Nat. Commun."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1093\/hmg\/ddz007","article-title":"Pharmacological modulation of the ER stress response ameliorates oculopharyngeal muscular dystrophy.","volume":"28","author":"Malerba","year":"","journal-title":"Hum. Mol. Genet."},{"key":"B24","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/978-3-030-03095-7_31","article-title":"Gene therapy for oculopharyngeal muscular dystrophy.","volume":"2019","author":"Malerba","year":"","journal-title":"Muscle Gene Ther."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1186\/2044-5040-1-21","article-title":"Aberrant repair and fibrosis development in skeletal muscle.","volume":"1","author":"Mann","year":"2011","journal-title":"Skelet. Muscle"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01486-4","article-title":"Downregulation of myostatin pathway in neuromuscular diseases may explain challenges of anti-myostatin therapeutic approaches.","volume":"8","author":"Mariot","year":"2017","journal-title":"Nat. Commun."},{"key":"B27","doi-asserted-by":"publisher","first-page":"217","DOI":"10.2174\/187152210793663810","article-title":"Metabolic functions of myostatin and GDF11.","volume":"10","author":"McPherron","year":"2010","journal-title":"Immunol. Endocr. Metab. Agents Med. Chem."},{"key":"B28","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/387083a0","article-title":"Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member.","volume":"387","author":"McPherron","year":"1997","journal-title":"Nature"},{"key":"B29","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/mt.2014.200","article-title":"A phase 1\/2a follistatin gene therapy trial for becker muscular dystrophy.","volume":"23","author":"Mendell","year":"2015","journal-title":"Mol. Ther."},{"key":"B30","doi-asserted-by":"publisher","first-page":"R444","DOI":"10.1152\/ajpregu.00377.2013","article-title":"Myostatin is a key mediator between energy metabolism and endurance capacity of skeletal muscle.","volume":"307","author":"Mouisel","year":"2014","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"4433","DOI":"10.1096\/fj.10-159608","article-title":"Antibody-directed myostatin inhibition in 21-mo-old mice reveals novel roles for myostatin signaling in skeletal muscle structure and function.","volume":"24","author":"Murphy","year":"2010","journal-title":"FASEB J."},{"key":"B32","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1210\/er.2008-0003","article-title":"Clinical, agricultural, and evolutionary biology of myostatin: a comparative review.","volume":"29","author":"Rodgers","year":"2008","journal-title":"Endocr. Rev."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1038\/ng.2772","article-title":"BMP signaling controls muscle mass.","volume":"45","author":"Sartori","year":"2013","journal-title":"Nat. Genet."},{"key":"B34","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/mus.880040406","article-title":"An autopsy study of a familial oculopharyngeal muscular dystrophy (OPMD) with distal spread and neurogenic involvement.","volume":"4","author":"Schmitt","year":"1981","journal-title":"Muscle Nerve"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0006418","article-title":"Hsp70 chaperones and type I PRMTs are sequestered at intranuclear inclusions caused by polyalanine expansions in PABPN1.","volume":"4","author":"Tavanez","year":"2009","journal-title":"PLoS One"},{"key":"B36","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1093\/hmg\/ddx431","article-title":"Myostatin inhibition using mRK35 produces skeletal muscle growth and tubular aggregate formation in wild type and TgACTA1D286G nemaline myopathy mice.","volume":"27","author":"Tinklenberg","year":"2017","journal-title":"Hum. Mol. Genet."},{"key":"B37","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1016\/S0960-8966(97)00085-0","article-title":"Morphological changes in muscle fibers in oculopharyngeal muscular dystrophy.","volume":"7","author":"Tome","year":"1997","journal-title":"Neuromuscul. Disord."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1093\/hmg\/ddq098","article-title":"Molecular and phenotypic characterization of a mouse model of oculopharyngeal muscular dystrophy reveals severe muscular atrophy restricted to fast glycolytic fibres.","volume":"19","author":"Trollet","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"B39","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/ana.21338","article-title":"A phase I\/IItrial of MYO-029 in adult subjects with muscular dystrophy.","volume":"63","author":"Wagner","year":"2008","journal-title":"Ann. Neurol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1002\/ana.10385","article-title":"Loss of myostatin attenuates severity of muscular dystrophy in mdx mice.","volume":"52","author":"Wagner","year":"2002","journal-title":"Ann. Neurol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1159\/000356740","article-title":"Myostatin and sarcopenia: opportunities and challenges-a mini-review.","volume":"60","author":"White","year":"2014","journal-title":"Gerontology"}],"container-title":["Frontiers in Physiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphys.2020.00184\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,5]],"date-time":"2020-03-05T05:47:23Z","timestamp":1583387243000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphys.2020.00184\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,5]]},"references-count":40,"alternative-id":["10.3389\/fphys.2020.00184"],"URL":"https:\/\/doi.org\/10.3389\/fphys.2020.00184","relation":{},"ISSN":["1664-042X"],"issn-type":[{"value":"1664-042X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,5]]},"article-number":"184"}}